$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Compounds and methods for synthesis of bicyclic nucleic acid analogs 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • C07H-021/00
출원번호 UP-0747042 (2007-05-10)
등록번호 US-7569686 (2009-08-24)
발명자 / 주소
  • Bhat, Balkrishen
  • Xia, Jie
  • Seth, Punit P.
  • Vasquez, Guillermo
  • Migawa, Michael T.
  • Allerson, Charles
  • Prakash, Thazha P.
  • Swayze, Eric E.
출원인 / 주소
  • Isis Pharmaceuticals, Inc.
대리인 / 주소
    Day, Jones
인용정보 피인용 횟수 : 113  인용 특허 : 121

초록

The present invention provides compounds and methods of using them for preparing bicyclic nucleosides. The bicyclic nucleosides are useful for preparing chemically modified oligomeric compounds. Oligomeric compounds comprising these bicyclic nucleosides have enhanced properties such as increased nu

대표청구항

What is claimed is: 1. A compound having formula I: wherein: R1 is H or a hydroxyl protecting group; R2 is H or a hydroxyl protecting group; R3 and R4 are each independently C1-C6 alkyl or substituted C1-C6 alkyl; and Q is an optionally substituted polycyclylic aromatic or heteroaromatic radical

이 특허에 인용된 특허 (121)

  1. Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
  2. Manoharan, Muthiah; Cook, Phillip Dan, 2'-O-aminoethyloxyethyl-modified oligonucleotides.
  3. Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
  4. Buhr Chris A. (Daly City CA) Matteucci Mark (Burlingame CA), 2\modified nucleoside and nucleotide compounds.
  5. Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
  6. Montgomery John A. (Birmingham AL) Secrist ; III John A. (Birmingham AL), 2′-deoxy-4′-thioribonucleosides and their antiviral activity.
  7. Usman Nassim (Boulder CO) Karpeisky Alexander (Boulder CO) Beigelman Leonid (Longmont CO) Modak Anil (Boulder CO), 2′deoxy-2′-alkylnucleotide containing nucleic acid.
  8. Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
  9. Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR) Stirchak Eugene P. (Corvallis OR), Alpha-morpholino ribonucleoside derivatives and polymers thereof.
  10. Agrawal Sudhir (Shrewsbury MA) Tang Jin-Yan (Shrewsbury MA), Aminoalkylphosphorothioamidate oligonucleotide deratives.
  11. Agrawal Sudhir (Shrewsbury MA) Tang Jin-Yan (Shrewsbury MA), Aminoalkylphosphotriester oligonucleotide derivatives.
  12. Switzer Christopher (Moreno Valley CA), Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides.
  13. De Mesmaeker Alain (Kaenerkinden CHX) Lebreton Jacques (Marseilles FRX) Waldner Adrian (Allschwil CHX) Cook Phillip D. (Carlsbad CA), Backbone modified oligonucleotide analogs.
  14. Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Morvan Francois (Montpellier FRX), Backbone modified oligonucleotide analogs and solid phase synthesis thereof.
  15. Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
  16. Sanghvi Yogesh S. (San Marcos CA) Cook Phillip D. (Vista CA), Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling.
  17. Leumann Christian (Zurich CHX), Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates.
  18. Leumann Christian (Zurich CHX), Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates.
  19. Imanishi, Takeshi; Obika, Satoshi, Bicyclonucleoside and oligonucleotide analogue.
  20. Imanishi Takeshi,JPX ; Obika Satoshi,JPX, Bicyclonucleoside and oligonucleotide analogues.
  21. Matteucci Mark D. (Burlingame CA) Cao Xiaodong (Carlsbad CA), Binding compentent oligomers containing unsaturated 3′,5′and 2′,5′linkages.
  22. Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
  23. Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
  24. Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
  25. Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
  26. Kmiec Eric B. (Malvern PA), Compounds and methods for site directed mutations in eukaryotic cells.
  27. Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
  28. Cook Phillip D. (San Marcos CA) Teng Kelly (San Diego CA), Conjugated 4′-desmethyl nucleoside analog compounds.
  29. Cook Phillip D. (Carlsbad CA) Baschang Gerhard (Bettingen CHX), Cyclobutyl oligonucleotide surrogates.
  30. Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
  31. Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Konstanz DEX), Dual action 2′,5′-oligoadenylate antiviral derivatives and uses thereof.
  32. Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), Encapsulated 2′,5′-phosphorothioate oligoadenylates.
  33. Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
  34. Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
  35. Froehler Brian C. (Belmont CA), Exonuclease-resistant oligonucleotides.
  36. Cook Phillip D. (Vista CA) Monia Brett P. (Carlsbad CA), Gapped 2′modified oligonucleotides.
  37. Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (Carlsbad CA), Heteroatomic oligonucleoside linkages.
  38. Teng Kelly (San Diego CA) Sanghvi Yogesh S. (San Marcos CA) Cook Phillip Dan (San Marcos CA), Heteroatomic oligonucleoside linkages.
  39. Schally Andrew V. ; Izdebski Jan, Highly potent agonists of growth hormone releasing hormone.
  40. Metelev Valeri (Shrewsbury MA) Agrawal Sudhir (Shrewsbury MA), Hybrid oligonucleotide phosphorothioates.
  41. Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Hydrogen phosphonodithioate compositions.
  42. Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
  43. Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
  44. Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
  45. Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
  46. Agrawal Sudhir (Shrewsbury MA), Inverted chimeric and hybrid oligonucleotides.
  47. Agrawal Sudhir (Shrewsbury MA) Tang Jin-Yan (Shrewsbury MA), Linear aminoalkylphosphoramidate oligonucleotide derivatives.
  48. Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
  49. Matteucci Mark D. (Burlingame CA) Zhang Jiancun (San Francisco CA), Method for oligonucleotide analog synthesis.
  50. Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
  51. Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
  52. Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
  53. Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
  54. Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
  55. Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
  56. Beaton Graham (Boulder CO) Fisher Eric F. (Boulder CO), Modified oligonucleotides and intermediates useful in nucleic acid therapeutics.
  57. Cook P. Dan (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA) Manoharan Muthiah (Carlsbad CA), N-2 substituted purines.
  58. Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
  59. Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
  60. Swaminathan Sundaramoorthi ; Matteucci Mark ; Jones Robert J. ; Pudlo Jeff ; Munger John, Nuclease stable and binding competent oligomers and methods for their use.
  61. Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA), Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled.
  62. Bischofberger Norbert W. (San Carlos CA) Matteucci Mark D. (Burlingame CA), Nucleic acid intercalating agents.
  63. Buhr Chris (Daly City CA) Matteucci Mark (Burlingame CA) Bischofberger Norbert W. (San Carlos CA) Froehler Brian (Belmont CA), Nucleoside 5′-methylene phosphonates.
  64. Haralambidis Jim (Victoria AUX), Nucleoside derivatives.
  65. Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues.
  66. Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (San Francisco CA), Nucleosides useful in the preparation of polynucleotides.
  67. Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa 상세보기
  • Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
  • Sanghvi Yogesh S. (Carlsbad CA) Cook Phillip D. (Carlsbad CA), Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms.
  • Hecht Sidney M. (Charlottesville VA), Oligonucleotide N-alkylphosphoramidates.
  • Bischofberger Norbert (San Carlos CA) Kent Ken (Mountain View CA) Wagner Rick (Burlingame CA) Buhr Chris (Daly City CA) Lin Kuei-Ying (Fremont CA), Oligonucleotide analogs capable of passive cell membrane permeation.
  • Benner Steven A. (Grossmannstrasse 16 ; #7 CH-8049 Zurich CHX), Oligonucleotide analogs containing sulfur linkages.
  • Matteucci Mark (Burlingame CA), Oligonucleotide analogs with novel linkages.
  • Matteucci Mark (Burlingame CA), Oligonucleotide analogs with novel linkages.
  • Huie Edward M. (Wilmington DE) Trainor George L. (Wilmington DE), Oligonucleotide analogs with sulfamate linkages.
  • Wengel, Jesper; Nielsen, Poul, Oligonucleotide analogues.
  • Weis Alexander Ludvik (Berwyn PA) Hausheer Frederick Herman (San Antonio TX) Chaturvedula Prasad Venkata Chala (Exton PA) Delecki Daniel Joseph (Radnor PA) Cavanaugh ; Jr. Paul Francis (West Chester , Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleo.
  • Chaturvedula Prasad Venkata Chala (Exton PA), Oligonucleotide dimers with amide linkages replacing phosphodiester linkages.
  • Tullis Richard H. (La Jolla CA), Oligonucleotide therapeutic agent and method of making same.
  • Maag Hans (Menlo Park CA) Rose Samuel J. (Mountain View CA) Schmidt Beat (Baltschieder CHX), Oligonucleotides containing 4′-substituted nucleotides.
  • Gmeiner William H. (Omaha NE) Iversen Patrick L. (Omaha NE), Oligonucleotides containing 5-fluorouracil.
  • Froehler Brian (Belmont CA) Jones Robert J. (Daly City CA), Oligonucleotides containing 5-propynyl pyrimidines.
  • Cook Phillip D. (San Marcos CA) Ramasamy Kanda S. (Laguna Hills CA) Manoharan Muthiah (Carlsbad CA), Oligonucleotides containing N-2 substituted purines.
  • Cook Phillip D. (San Marcos CA) Hoke Glenn (Mt. Airy MD), Oligonucleotides having phosphorothioate linkages of high chiral purity.
  • Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
  • Froehler Brian, Oligonucleotides with inverted polarity.
  • Froehler Brian (Belmont CA), Oligonucleotides with inverted polarity.
  • Froehler Brian (Belmont CA), Oligonucleotides with inverted polarity.
  • Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
  • Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Oligonucleotides with selectably cleavable and/or abasic sites.
  • Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
  • Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
  • Barascut Jean-Louis (Combaillaux FRX) Imbach Jean-Louis (Montpellier FRX), Oligothionucleotides.
  • Cook Phillip Dan (Carlsbad CA), PNA-DNA-PNA chimeric macromolecules.
  • Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Boulder CO), Phosphoramidite compounds and processes.
  • Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
  • Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Mountain View CA), Phosphoramidite nucleoside compounds.
  • Maddry Joseph A. (Birmingham AL) Reynolds Robert C. (Birmingham AL) Secrist John A. (Birmingham AL) Montgomery John A. (Birmingham AL) Crooks Peter A. (Lexington KY), Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages.
  • Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
  • Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO), Polynucleotide phosphorodithioates.
  • Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
  • Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Mountain View CA), Process for oligonucleo tide synthesis using phosphormidite intermediates.
  • Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (Boulder CO), Process for preparing polynucleotides.
  • Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (Boulder CO), Process for preparing polynucleotides.
  • McGee Daniel Peter Claude (Boulder CO), Process for the preparation of 2′-O-alkyl purine phosphoramidites.
  • Kster Hubert (Concord MA) Sinha Nanda D. (San Rafael CA), Process for the preparation of oligonucleotides.
  • Kster Hubert (Hamburg DEX) Sinha Nanda D. (Bundu Dt. Ranchi INX), Process for the preparation of oligonucleotides.
  • Weis Alexander L. (Berwyn PA) Saha Ashis K. (Frazer PA) Hausheer Frederick H. (San Antonio TX), Process of linking nucleosides with a siloxane bridge.
  • Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
  • Matteucci Mark ; Jones Robert J. ; Lin Kuei-Ying, Pyrimidine derivatives.
  • Matteucci Mark D. (Burlingame CA) Jones Robert J. (Millbrae CA) Lin Kuei-Ying (Fremont CA), Pyrimidine derivatives for labeled binding partners.
  • Matteucci Mark D. ; Jones Robert J., Pyrimidine derivatives for labeled binding partners.
  • Acevedo Oscar L. (San Diego CA) Hebert Normand (San Marcos CA), Pyrrolidine-containing monomers and oligomers.
  • Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Sequence-specific binding polymers for duplex nucleic acids.
  • Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Sequence-specific binding polymers for duplex nucleic acids.
  • Agrawal, Sudhir; Tang, Jinyan, Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling.
  • Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
  • Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
  • Cook Phillip Dan (Carlsbad CA) Kawasaki Andrew Mamoro (Oceanside CA), Sugar modified oligonucleotides that detect and modulate gene expression.
  • Summerton, James E.; Weller, Dwight D., Uncharged morpholino-based polymers having achiral intersubunit linkages.
  • Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
  • 이 특허를 인용한 특허 (113)

    1. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda, Antagonat compositions and methods of use.
    2. Edinger, Aimee; Hanessian, Stephen, Azacyclic constrained analogs of FTY720.
    3. Imanishi, Takeshi; Orita, Ayako; Ban, Ikuya, BNA clamp method.
    4. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E., Compositions and methods.
    5. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E., Compositions and methods for modulating HBV expression.
    6. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E., Compositions and methods for modulating HBV expression.
    7. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Freier, Susan M.; Graham, Mark J.; Crooke, Rosanne M., Compositions and methods for modulating angiopoietin-like 3 expression.
    8. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Graham, Mark J., Compositions and methods for modulating apolipoprotein (a) expression.
    9. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Graham, Mark J., Compositions and methods for modulating apolipoprotein (a) expression.
    10. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Graham, Mark J., Compositions and methods for modulating apolipoprotein C-III expression.
    11. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Graham, Mark J., Compositions and methods for modulating apolipoprotein C-III expression.
    12. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Bhanot, Sanjay; Freier, Susan M.; Bui, Huynh-Hoa, Compositions and methods for modulating growth hormone receptor expression.
    13. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E., Conjugated antisense compounds and their use.
    14. Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E., Conjugated antisense compounds and their use.
    15. Woolf, Tod, Double-stranded oligonucleotides.
    16. Woolf, Tod; Wiederholt, Kristin, Double-stranded oligonucleotides.
    17. Woolf, Tod; Wiederholt, Kristin, Double-stranded oligonucleotides.
    18. Oestergaard, Michael; Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E., Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof.
    19. Brown, David; Ford, Lance P.; Jarvis, Richard A.; Pallotta, Vince; Pasloske, Brittan L., High potency siRNAS for reducing the expression of target genes.
    20. Bennett, C. Frank; Freier, Susan M.; Pulst, Stefan M.; Scoles, Daniel R.; Hung, Gene, Methods for modulating Ataxin 2 expression.
    21. Behlke, Mark; Owczarzy, Richard; Rose, Scott D.; Tataurov, Andrey; You, Yong, Methods for predicting stability and melting temperatures of nucleic acid duplexes.
    22. Wahlestedt, Claes, Natural antisense and non-coding RNA transcripts as drug targets.
    23. Wahlestedt, Claes, Natural antisense and non-coding RNA transcripts as drug targets.
    24. Oestergaard, Michael; Swayze, Eric E.; Seth, Punit P., Oligomeric compounds comprising alpha-beta-constrained nucleic acid.
    25. Woolf, Tod; Taylor, Margaret, Oligonucleotide compositions with enhanced efficiency.
    26. Woolf, Tod; Taylor, Margaret, Oligonucleotide compositions with enhanced efficiency.
    27. Woolf, Tod; Taylor, Margaret, Oligonucleotide compositions with enhanced efficiency.
    28. Woolf, Tod; Taylor, Margaret, Oligonucleotide compositions with enhanced efficiency.
    29. Seth, Punit P.; Prakash, Thazha P., Targeted therapeutic nucleosides and their use.
    30. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
    31. Collard, Joseph; Khorkova Sherman, Olga, Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1.
    32. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ).
    33. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin.
    34. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
    35. Collard, Joseph; Khorkova Sherman, Olga, Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT.
    36. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
    37. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
    38. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
    39. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    40. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    41. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    42. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
    43. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
    44. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
    45. Collard, Joseph; Khorkova Sherman, Olga, Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ).
    46. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
    47. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
    48. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    49. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    50. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    51. Collard, Joseph; Khorkova, Olga, Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1.
    52. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    53. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    54. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    55. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    56. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
    57. Faghihi, Mohammad Ali; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
    58. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3.
    59. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
    60. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
    61. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
    62. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
    63. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    64. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    65. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    66. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
    67. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
    68. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
    69. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
    70. Collard, Joseph; Khorkova Sherman, Olga, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
    71. Collard, Joseph; Sherman, Olga Khorkova, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
    72. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
    73. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
    74. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity.
    75. Collard, Joseph; Khorkova Sherman, Olga, Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
    76. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
    77. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
    78. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS).
    79. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3).
    80. Collard, Joseph; Khorkova Sherman, Olga, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
    81. Collard, Joseph; Sherman, Olga Khorkova, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
    82. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
    83. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
    84. Collard, Joseph; Khorkova Sherman, Olga, Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
    85. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2.
    86. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
    87. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
    88. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
    89. Collard, Joseph; Khorkova Sherman, Olga, Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
    90. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1.
    91. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
    92. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
    93. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
    94. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
    95. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG.
    96. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4.
    97. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; De Leon, Belinda, Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT).
    98. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda; Coito, Carlos; Hsiao, Jane H., Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA.
    99. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
    100. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
    101. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
    102. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
    103. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
    104. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
    105. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
    106. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
    107. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
    108. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
    109. Collard, Joseph; Khorkova Sherman, Olga, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
    110. Collard, Joseph; Sherman, Olga Khorkova, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
    111. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP.
    112. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP.
    113. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
    섹션별 컨텐츠 바로가기

    AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

    AI-Helper 아이콘
    AI-Helper
    안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
    ※ AI-Helper는 부적절한 답변을 할 수 있습니다.

    선택된 텍스트

    맨위로